Drugs & Therapy Perspectives

, Volume 16, Issue 2, pp 1–5 | Cite as

Palivizumab: preferred agent for prevention of RSV infection in high risk infants

New drugs and disease management


Respiratory Syncytial Virus Kawasaki Disease Respiratory Syncytial Virus Infection Palivizumab Humanize Respiratory Syncytial Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999 Mar; 18(3): 223–31PubMedCrossRefGoogle Scholar
  2. 2.
    Scott LJ, Lamb HM. Palivizumab. Drugs 1999 Aug; 59(2): 305–11CrossRefGoogle Scholar
  3. 3.
    American Academy of Pediatrics Committee on Infectious Disease and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211–1216CrossRefGoogle Scholar
  4. 4.
    Robinson RF, Nahata MC. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. Am J Health-Syst Pharm 2000 Feb 1; 57: 259–64PubMedGoogle Scholar
  5. 5.
    Medlmmune Inc. Synagis™ (palivizumab) package insert. 1998 Jun 19Google Scholar
  6. 6.
    Medlmmune Inc. RespiGam™ (respiratory syncytial virus immune globulin intravenous (human) [RSV-IGIV]) package insert. 1996 MarGoogle Scholar
  7. 7.
    Red book. Montvale (NJ): Medical Economics Company, 1999Google Scholar
  8. 8.
    British National Formulary No. 39. London: The Pharmaceutical Press, 2000 Mar; 297Google Scholar
  9. 9.
    IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998 Sep; 102 (Part 1): 531–37CrossRefGoogle Scholar
  10. 10.
    Marchetti A, Lau H, Magar R, et al. Expected economic impact of respiratory syncytial virus (RSV) prophylaxis [abstract no. 1592]. Pediatr Res 1999 Apr; 45 (Part 2): 270ACrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Personalised recommendations